Introduction
============

Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly in the Western world [@b1]--[@b3]. The late neovascular subtype, occurring in approximately 10% of patients, is responsible for severe visual impairment and is characterized by the growth of blood vessels from the choroid through Bruch\'s membrane, resulting in choroidal neovascularization (CNV). The visual decline observed in these patients as a result of CNV can be attributed in part to aberrant neovascularization, vasculogenesis/angiogenesis and, in part, to fibrosis [@b4]--[@b6]. Current treatments target leakage of vessels but are ineffective in treating fibrosis [@b4],[@b7],[@b8]. Therefore, identification of pathogenic mechanisms involved in all aspects of neovascularization is a critical step in developing more successful therapies. Multiple genetic and environmental risk factors for AMD have been identified to date [@b9]--[@b11], which, independently or in combination, may lead to pathological changes in the structural integrity and function of retinal pigment epithelial (RPE) and choroidal endothelial cells, the cells compromised in CNV formation. Although the specific signalling pathways and biomolecular events which cause cellular dysfunction in AMD are not well understood, RNA transcriptome analysis of eyes from human AMD donors suggest that diverse pathogenic pathways, including angiogenesis, extracellular matrix (ECM) remodelling, inflammation and the immune response, are perturbed in RPE cells [@b12],[@b13]. This fact, along with putative crosstalk between RPE cells and the immune and vascular axes, underscores the need to study RPE cells along with other cell types within the microenvironment, eg endothelial cells of the choriocapillaris and choroid, and immune cells including macrophages, when investigating potential pathogenic mechanisms of AMD.

The aryl hydrocarbon receptor (AhR) is a member of the bHLH/PAS (basic helix--loop--helix/Per--Arnt--Sim) family of heterodimeric transcriptional regulators. AhR is important in mediating cellular responses to a wide variety of environmental contaminants, including polycyclic aromatic hydrocarbons, constituents of cigarette smoke and by-products of industrial combustion and automobile exhausts [@b14]--[@b17]. Functionally, AhR has been shown to play a critical role in vascular development, angiogenesis and cancer [@b18]--[@b21], and deficiency in its activity has been linked to peripheral vascular disease, atherosclerosis and tumour development [@b20]--[@b23]. Recently, we found that dysfunction of the *AhR* signalling pathway in aged mice results in pathological features of dry AMD *in vivo* [@b24]. Moreover, we discovered that the activity of the receptor in human primary RPE cell lines decreases as a function of age, suggesting a potential age-related compromise in normal RPE cellular clearance mechanisms. This is interesting in light of other studies reporting decreased *AhR* expression as a function of age in multiple organs of mice, rats and rabbits [@b25]--[@b27]. Finally, we observed an age-related thinning of the choroidal vascular layers in mice harbouring the *AhR* null allele (*AhR^−/−^*). These findings, along with the reported regulatory role of AhR in angiogenesis, led us to hypothesize that the *AhR* signalling pathway may regulate pathogenic processes of neovascular AMD. To test this hypothesis, we: (a) investigated the RNA profile of the RPE-choroid of *AhR^−/−^* mice; (b) evaluated the severity and morphology of experimentally-induced CNV lesions in *AhR^−/−^* mice; (3) examined the effect of *AhR* knock-down on endothelial cell proliferation and migration; and (d) measured the expression of angiogenic, inflammatory and ECM representative genes altered in human CNV, in RPE and choroidal endothelial cell culture models following *AhR* knock-down. The findings support the hypothesis that the AhR plays a role in regulating ECM deposition, immune cell recruitment and angiogenesis, events which constitute necessary steps in the pathogenesis of AMD.

Materials and methods
=====================

Animals
-------

Mice used included *AhR^−/−^* mice (B6.129-AhR\^tm1Bra/J) [@b28] originally obtained from Jackson Laboratory (Bar Harbour, ME, USA), where they were bred for 10 generations to C57BL6 mice and an additional two generations to C57BL/6 J mice. At Duke University, within the Division of Laboratory Animal Resources, over the last several years they have been bred a minimum of six generations to the 6 J background. Additionally, the mice were screened for the confounding retinal degeneration 8 mutation and its absence was confirmed as previously described [@b24]. Our study protocol was approved by the Duke University Institutional Animal Care and Use Committee. All animal experiments were performed in accordance with the guidelines of the ARVO statement for the Use of Animals in Ophthalmic and Vision Research.

RNA sequencing (RNA-seq) and pathway generation analysis
--------------------------------------------------------

Mouse RPE-choroid tissue mRNA libraries were prepared using a TruSeq kit (Illumina, San Diego, CA, USA) [@b29],[@b30]. RPE-choroid pooled from eyes (*n =* 2) was used for each library preparation. Three biological replicate libraries were made from 11--13 month-old *AhR^−/−^* and wt mice. Six murine eye libraries were run on two non-independent lanes of the Illumina HiSeq 2500 at the Duke Genome Sequencing and Analysis Core Facility, using 100 bp single-end sequencing. Following quality assessment (FastQC), reads were mapped onto to the University of California Santa Cruz mm10 mouse genome assembly, using TopHat 1.4.0 with Bowtie 0.12.5 alignment engine. Read counts/feature were calculated using HTSeq-count [@b31], with intersection strict option and using a predefined annotation of known genes from the mm10 genome assembly. Differential transcript abundance was calculated with EdgeR [@b32],[@b33], utilizing the exactTest procedure. Genes with fewer than one fragments/kilobase of exon/million fragments mapped (FPKM) in more than two samples out of a total of six were not used in differential expression calculations. Significance was defined based on Benjamini--Hochberg false discovery rate (FDR) *q* values at 0.05 levels. Functional annotation, over-representation analysis and pathway analysis were performed using the GeneGo Metacore pathways software (MetaCore™ v 6.18, build 65505, Thomson Reuters, New York, NY, USA), based on the list of differentially regulated genes produced by EdgeR. False discovery rate was controlled by FDR procedure. The gene ontology (GO) biological process database was used to evaluate functional enrichment.

Mouse model of CNV
------------------

Laser photocoagulation was performed in cohorts of young and old wt and *AhR^−/−^* mice (4 months old, *n =* 8/genotype; and 11--13 months old, *n =* 20/genotype), as previously described [@b34]. Briefly, four thermal burns were induced in each eye around the optic nerve, using a slit lamp delivery system. The mice were euthanized 3 weeks after laser treatment and the eyes were harvested for visualization of laser-induced CNV in posterior pole flat-mounts, or cryopreserved for immunohistochemistry and morphology experiments, as described in Supplementary materials and methods (see supplementary material). CNV lesion volume, area and size were measured in flat-mounts stained with propidium iodide to evaluate cellularity, or isolectin GS-IB~4~ to examine vascularity, of the neovascular lesion, as described in Supplementary materials and methods.

Cell culture, siRNA transfection and functional assays
------------------------------------------------------

Cell lines obtained from ATCC (Manassas, VA, USA) included RF/6A cells, a spontaneously transformed choroidal endothelial cell line derived from the eyes of a rhesus macaque fetus, passages 35--40, and ARPE19 cells, a spontaneously arising human RPE cell line derived from the eyes of a 19 year-old male donor, passages 21--28. Primary cell cultures used included RPE cells (1° RPE) isolated from donor eyes older than 60 years, collected from the North Carolina Organ Donor and Eye Bank Inc. \< 6 h post-mortem and cultured within 24 h in accordance with the Declaration of Helsinki for research involving human tissue, as previously described [@b24]. Small interfering RNAs (siRNAs) were used to knock down *AhR* in cultures of ARPE19, 1° RPE and RF/6A endothelial cells for cell proliferation and viability assays, scrape wound migration assays (MEM 1% CS-FBS), tube formation assays (MEM 1% FBS) and AhR activity assays (7.5% CS-FBS), as described in Supplementary materials and methods (see supplementary material). RNA and protein were extracted at the indicated time points for quantitative real-time PCR (qPCR) and western blot assays. Primer sequences, list of antibodies and dilutions used are provided in Tables S1 and S2 (see supplementary material).

Statistical analysis and data collection
----------------------------------------

Statistical methods for data analysis other than the RNA-seq experiment included two-tailed Student\'s *t*-test and two-way ANOVA, with Sidak\'s multiple comparison test using GraphPad Prism. Values were considered statistically significant at *p \<* 0.05. Each *in vitro* experiment was repeated a minimum of three times. Western blots, migration and tube-formation assays shown are representative of a minimum of three independent experiments.

Results
=======

Transcriptomic analysis reveals *AhR* contributions to multiple AMD-related pathways
------------------------------------------------------------------------------------

RNA-seq revealed 392 transcripts differentially expressed between RPE-choroid tissues isolated from aged wt and *AhR^−/−^* mouse eyes. The general distribution of differential gene expression as a function of transcript abundance (M--A plot) is shown in [Figure 1](#fig01){ref-type="fig"}A. Annotation performed using MetaCore (Thomson Reuters) pathway software, in conjunction with over-representation analysis of GO terms, highlighted the enrichment of genes in several functional categories (see supplementary material, [Table S5](#sd13){ref-type="supplementary-material"}). Among these, we focused on GO terms: (a) \'Extracellular matrix organization\', GO:0030198 (FDR *p* value 3.137 × 10^−6^, 26 of 420 genes present in the list); (b) \'Inflammatory response\', GO:0006954 (FDR *p* value 3.577 × 10^−6^, 32 of 610 genes); and (c) \'Angiogenesis\', GO:0001525 (FDR *p* value 5.757 × 10^−4^, 20 of 394 genes). We cross-validated the RNA-seq data from each functional category in *AhR^−/−^* and wt mouse RPE-choroid samples using qPCR ([Figure 1](#fig01){ref-type="fig"}B); primers are listed in [Table S3](#sd11){ref-type="supplementary-material"} (see supplementary material). We observed down-regulation of *Gpr124*, a regulator of angiogenesis also known as tumour endothelial factor 5 [@b35],[@b36], down-regulation of the ECM gene collagen type V *α*1 (*Col5a1*) and up-regulation of the inflammatory gene chemokine (C--C motif) receptor 1 (*Ccr1*) [@b37],[@b38]. These genes displayed a significant fold change, the direction and magnitude of which was consistent with the RNA-seq analysis.

![Perturbations of gene expression in RPE-choroid tissue from 11--13 month-old *AhR^−/−^* versus wild-type mice. (A) Horizontal axis, log10 of average counts/million (CPM) bases across all samples; vertical axis, log2 of fold change (FC) between knock-out and wild-type animals; each dot represents a feature (gene). Genes regulated at significance level of 0.05 after adjustment for multiple comparisons by FDR are highlighted; up-regulation (red) or repression in knock-out (blue) compared to wild-type. A total of 268 genes are up-regulated in knock-out, while 124 are repressed; red horizontal dashed lines indicate two-fold change level. Among the induced genes, 205 of 268 genes are up-regulated by \> 2-fold, while among the repressed genes, 44 of 124 are repressed by \> 2-fold; all significantly regulated genes are regulated by \> 1.5-fold. (B) qPCR validation of select angiogenic \[*Gpr124* and hypoxia inducible factor 3 (*Egln3*)\], extracellular matrix (ECM; *Mmp13* and *Col5a1*) and inflammatory (*Ccr1* and *C3*) genes in *AhR^−/−^* and wt mouse RPE/choroid samples (*n =* 3/genotype; ^\*^*p \<* 0.05, ^\*\*^*p \<* 0.01; ns, not significant). Table illustrates fold change as seen by RNA-seq compared to qPCR](path0235-0101-f1){#fig01}

*AhR^−/−^* mice develop large CNV lesions compared to age-matched wild-type mice
--------------------------------------------------------------------------------

To determine whether AhR plays a role in the development of CNV, we measured the size, volume and cellularity of laser-induced CNV lesions in flat-mounts of posterior eye cups from 11--13 month-old wt or *AhR^−/−^* mice, stained with propidium iodide ([Figure 2](#fig02){ref-type="fig"}A). Larger lesions developed in the eyes of *AhR^−/−^* mice (Figure 2Avii--x) compared to wt (Figure 2Ai--iv), along with a gene-dependent variability in the number of mice with single versus merged lesions ([Figure 2](#fig02){ref-type="fig"}B). Specifically, a greater number of *AhR^−/−^* mice presented with three or four merged lesions compared to wt mice (Figure 2Avii--x), which developed at most two merged lesions (Figure 2Aiii, iv). Quantitatively, the mean CNV lesion area was significantly higher in *AhR^−/−^* mice compared with that in wt controls ([Figure 2](#fig02){ref-type="fig"}C; normalized to wt, *p \<* 0.001). Measurements of CNV lesion thickness and volume determined from *z*-stacks and three-dimensional (3D) reconstruction of images spanning the lesion confirmed a significantly larger lesion volume in *AhR^−/−^* mice versus wt controls. ([Figure 2](#fig02){ref-type="fig"}D, E; normalized to wt, *p \<* 0.0001, *p \<* 0.05; see also supplementary material, [Figure S2](#sd3){ref-type="supplementary-material"}). Furthermore, vascularity as visualized in flat-mounts stained with isolectin GS-IB~4~ confirmed an *AhR*-dependent increase in the laser-induced vascular lesion and vessel sprouting (Figure 2Avi, xii). Finally, to determine whether neovascular lesion exacerbation is a result of *AhR* knock-out or a consequence of age, we examined CNV cellularity and vascularity in eyes of 4 month-old *AhR^−/−^* and wt mice (*n =* 8/cohort; [Figure 3](#fig03){ref-type="fig"}A) and found a significant increase in lesion area in the knock-out compared to wt mice. ([Figure 3](#fig03){ref-type="fig"}B, C). This confirms that the role of *AhR* in CNV lesion formation is due to the absence of a functional gene, rather than being a developmental phenomenon.

![*AhR* regulates laser-induced CNV in aged mice. (A) Choroidal flat-mounts were prepared from 11--13 month-old laser-induced CNV mice (*n =* 20/genotype) and stained with propidium iodide (*AhR^−/−^*, *AhR* knock-out; ON, optic nerve; i--iv, wt; vii--x, *AhR^−/−^*; and isolectin GS-IB~4~, v--vi, wt; xi--xii, *AhR^−/−^*). Representative images from four eyes/genotype are shown to demonstrate individual and merged CNV lesions (dotted circles demarcate lesions and ON, i and vii) stained with propidium iodide; vi and xii, high-magnification images of individual lesions stained with isolectin GS-IB~4~. (B) Distribution of number of animals with individual versus merged lesions in wt and *AhR^−/−^* (*n =* 18/genotype). (C) Relative lesion area/animal was measured using ImageJ (mean and SEM; *n =* 18/genotype; ^\*\*^*p \<* 0.001). (D) Relative lesion thickness/animal (mean, SEM and data points for each group; *n =* 9/genotype; ^\*\*\*^*p \<* 0.0001); inserts display representative 3D reconstruction images for wt and *AhR^−/−^* mice. (E) Relative lesion volume/animal (mean and SEM for each group; *n =* 5/genotype; ^\*^*p \<* 0.05)](path0235-0101-f2){#fig02}

![AhR regulates laser-induced CNV in young mice. (A) Choroidal flat-mounts were prepared from 4 month-old laser-induced CNV mice (*n =* 8/genotype) and stained with propidium iodide (*AhR^−/−^*, *AhR* knock-out; ON, optic nerve; i, wt; ii, *AhR^−/−^*) and isolectin GS-IB~4~ (iii, wt; iv, *AhR^−/−^*); arrowhead, vessels sprouting and extending out from the CNV lesion: representative images are shown (dotted circles demarcate lesions and ON). (B) Relative lesion area/animal measured in propidium iodide stained flat-mounts (mean and SEM; *n =* 5/group; ^\*^*p \<* 0.05). (C) Relative lesion area/animal measured in isolectin GS-IB~4~-stained flat-mounts (mean and SEM; *n =* 8/group; ^\*\*^*p \<* 0.01)](path0235-0101-f3){#fig03}

AhR signalling pathway is active in ARPE19 and RF6A choroidal endothelial cell lines
------------------------------------------------------------------------------------

Both the RPE and endothelial cells of the choriocapillaries and choroid play a role in CNV formation [@b8],[@b34]. Previously, we have shown that the AhR signalling pathway is active in human RPE cells [@b24]. Here, we investigated the AhR signalling pathway in choroidal endothelial cells by determining the expression and activity of the receptor *in vitro*, using RF/6A cells. *AhR* and its obligate binding partner AhR nuclear translocator (*ARNT*) were found to be expressed in both RF/6A cells and excised human choroid specimens ([Figure 4](#fig04){ref-type="fig"}A). Following validation of the efficiency of RNA and protein knock-down using three different siAhRs in endothelial cells at 48 and 72 h ([Figure 4](#fig04){ref-type="fig"}B, C; see also supplementary material, [Figure S3](#sd4){ref-type="supplementary-material"}), we assessed AhR transcriptional activity and target gene expression in cells treated with known AhR agonists \[2,3,7,8-tetracholorodibenzodioxin (TCDD), benzo(*a*)pyrene (BAP), *β*-napthoflavone (*β*NF) and *α*-napthoflavone (*α*NF) (see supplementary material, [Table S4](#sd12){ref-type="supplementary-material"}). AhR agonists activated the receptor in RF/6A cells, while agonist-induced AhR activation was diminished upon receptor knock-down ([Figure 4](#fig04){ref-type="fig"}D). Expression of two AhR-specific target genes \[cytochrome P450, family 1, subfamily A, polypeptide 2 (*CYP1A2*) and CYP1, subfamily B, polypeptide 1, (*CYP1B1*)\] increased following agonist treatment and once again diminished following knock-down in RF/6A cells ([Figure 4](#fig04){ref-type="fig"}E, F; see also supplementary material, [Figure S3](#sd4){ref-type="supplementary-material"}), supporting the presence of an active AhR signalling pathway in the RF/6A choroidal endothelial cell line.

![AhR pathway is active in choroidal RF/6A cells. (A) Agarose gel of PCR analysis of *AhR* and its obligate binding partner *ARNT* in RF/6A cells and human choroid tissue samples; 36B4 was used as loading control. (B) Western blot of *AhR* knock-down in RF/6A at 48 and 72 h (siC, control siRNA; siAhR5, *AhR* siRNA; *n =* 3, representative image shown); *β*-actin was used as loading control. (C) Expression of *AhR* in siC- and siAhR5-treated cells in response to known AhR agonists (TCDD, BAP, *β*NF) and a partial AhR agonist (*α*NF); DMSO was used as a control (*n =* 3). (D) AhR activity in RF/6A cells transfected with the AhR--tk--luciferase reporter and siC or siAhR; cells were treated with AhR agonists or DMSO as control (*n =* 3): a, *p \<* 0.05 relative to DMSO-treated cells; b, *p \<* 0.05 relative to drug--siC-treated cells (*p* \< 0.05). (E) Expression of *CYP1A2* and (F) *CYP1B1* mRNA in siC- and siAhR-treated cells in response to AhR agonists or DMSO as a control (*n =* 3); a, *p \<* 0.05 relative to DMSO-treated cells; b, *p \<* 0.05 relative to drug-siC-treated cells; ns: not significant](path0235-0101-f4){#fig04}

*AhR* loss results in increased endothelial migration and tube formation
------------------------------------------------------------------------

A key process in neovascularization is cellular organization, which involves endothelial cell migration and sprouting, leading to the formation of an endothelial network [@b39]. To investigate the effect of *AhR* expression on choroidal endothelial cell migration, a scrape-wound assay was performed on RF/6A cells ([Figure 5](#fig05){ref-type="fig"}A). A significantly greater number of cells migrating into the wound were found following knock-down ([Figure 5](#fig05){ref-type="fig"}B; *p \<* 0.0001). We also determined the effect of *AhR* loss on the ability of endothelial cells to re-organize and form a 3D network, indicative of vascular morphogenesis ([Figure 5](#fig05){ref-type="fig"}C). Total tube lengths were significantly longer in cells transfected with siRNAs targeting the *AhR* compared with control ([Figure 5](#fig05){ref-type="fig"}D; *p \<* 0.0001). Suramin served as an additional control, inhibiting tube formation ([Figure 5](#fig05){ref-type="fig"}C). Cell viability and proliferation assays showed no significant differences between siC- and siAhR-transfected RF/6A cells (see supplementary material, [Figure S4](#sd5){ref-type="supplementary-material"}), or treatment with conditioned media following *AhR* knock-down (see supplementary material, [Figure S5](#sd6){ref-type="supplementary-material"}), indicating that the increase in migration and tube formation is not due to a change in cell viability or proliferation. Cumulatively, these results suggest that the loss of *AhR* expression and/or activity may drive endothelial cells towards a pro-angiogenic phenotype.

![*AhR* knock-down increases endothelial migration and tube formation. (A) The effect of *AhR* loss on migration of RF/6A cells was analysed in a wound-healing assay (*n =* 3, representative images at *t* = 0 and *t* = 36 h are shown); dotted lines demarcate the boarders of the scrape wound. (B) The cells migrating into the wound were counted using ImageJ (mean and SEM; *n =* 3; ^\*^*p \<* 0.0001). (C) The effect of *AhR* loss on tube formation in RF/6A cells was analysed by an angiogenesis assay in Geltrex™ (*n =* 3; representative images at *t* = 3 h are shown). Suramin, an inhibitor of tube formation, was used as a negative control. (D) Quantification of tube length in Geltrex™ using ImageJ (mean and SEM; *n =* 3; ^\*^*p \<* 0.0001); siC, control siRNA; siAhR5, AhR siRNA](path0235-0101-f5){#fig05}

*AhR* loss results in increased expression of inflammatory and angiogenic markers
---------------------------------------------------------------------------------

Inflammation has been shown to play a central role in AMD pathogenesis, as activated microglial cells have been detected in the subretinal space of AMD patients [@b40]. Microglia are normally excluded from the outer retina, due to the presence of immunosuppressive factors secreted by RPE cells [@b41]--[@b44]. In advanced age and following photoreceptor injury, retinal microglia migrate and accumulate within the outer retina [@b40]--[@b42],[@b45] and the neovascular lesion [@b46]. It is of significance, therefore, that we found an increased number of Iba1^+^ ([Figure 6](#fig06){ref-type="fig"}A) and macrophage chemotactic factor secreted phosphoprotein 1 (SPP1; see supplementary material, [Figure S6A](#sd7){ref-type="supplementary-material"})-positive cells within the CNV lesions after laser-induced injury in *AhR^−/−^* mice compared to wt mice ([Figure 6](#fig06){ref-type="fig"}B; see also supplementary material, [Figure S6B](#sd7){ref-type="supplementary-material"}; *p \<* 0.001 and *p \<* 0.01). Notably, we have also detected Iba1^+^ cells subretinally in aged *AhR^−/−^* in the absence of laser-induced CNV ([Figure 6](#fig06){ref-type="fig"}A). Since RPE and choroidal endothelial cells are involved in modulating the microenvironment of the outer retina secondary to the production and secretion of various cytokines and growth factors, we evaluated the impact of *AhR* loss on the expression of immunomodulatory and inflammatory cytokines/growth factors in ARPE19 and RF/6A cells. A significant increase in expression of chemokine (C--C motif) ligand 2 (*CCL2*) mRNA, important in microglial and macrophage recruitment, and vascular endothelial growth factor A (*VEGFA*) mRNA in ARPE19 cells, was found following *AhR* knock-down ([Figure 6](#fig06){ref-type="fig"}C; *AhR p \<* 0.0001, *VEGFA p \<* 0.01, *CCL2 p \<* 0.0001). In RF/6A cells we observed an increase in transforming growth factor-*β*1 (*TGFB1*) mRNA levels, which may contribute to subretinal fibrosis [@b47], an up-regulation of *SPP1* and down-regulation of the anti-angiogenic factor, *SERPINF1* ([Figure 6](#fig06){ref-type="fig"}D; *AhR p \<* 0.01, *TGFB1 p \<* 0.001, *SPP1 p \<* 0.001, *SERPINF1 p \<* 0.05) [@b48],[@b49].

![*AhR* regulates microglial infiltration and angiogenesis in CNV lesions. (A) Iba1 immunopositive cells (red) accumulate subretinally in 11--13 month-old *AhR^--/--^* mice (top right) and within laser-induced CNV lesions of *AhR^--/--^* mice (bottom right); Iba1^+^ cells are absent from the subretinal region in wt mice (top left) and decreased in wt CNV lesions (bottom left); dotted oval demarcates the lesion area in the bottom panels; nuclei are stained blue with Hoechst; representative images are shown; scale bar = 50 µm. (B) The numbers of Iba1^+^ cells in the CNV lesions of wt and *AhR^--/--^* mice were counted using ImageJ (mean and SEM; *n =* 4/group; ^\*^*p \<* 0.001). (C, D) Effect of *AhR* loss on *VEGFA*, *PDGFFB*, *TGFB1*, *CCL2*, *SPP1* and *SERPINF1* mRNA expression, using qPCR in (C) ARPE19 cells (mean and SEM; *n =* 3; ^\*^*p \<* 0.01, ^\*\*\*^*p \<* 0.0001) and (D) RF/6A cells (mean and SEM; *n =* 3; ^\*^*p \<* 0.05, ^\*\*^*p \<* 0.001, ^\*\*\*^*p \<* 0.0001); siC, control siRNA; siAhR5, AhR siRNA; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; ns, not significant](path0235-0101-f6){#fig06}

*AhR* loss results in increased expression of collagen
------------------------------------------------------

Impaired regulation of ECM turnover is a proposed AMD pathogenic mechanism [@b4],[@b50]. Further, the ECM molecule, COL4, is a component of sub-RPE deposits and CNV membranes [@b51],[@b52]. ECM turnover is also regulated in part by AhR in the liver, heart and kidneys [@b18],[@b53],[@b54]. Recently, we showed that COL4 is a component of the sub-RPE deposits that accumulate in aged *AhR^−/−^* mouse eyes, and demonstrated increased secretion of this protein from ARPE19 and primary human RPE cells following *AhR* knock-down *in vitro* [@b24]. With this in mind, and given that sub-RPE deposits, including drusen, are risk factors for the development of CNV, we assessed COL4 deposition in the laser-induced CNV lesions of *AhR^−/−^* versus wt mice. A marked increase in the quantity of COL4 staining within lesions in *AhR^−/−^* as compared to wt mice was noted ([Figure 7](#fig07){ref-type="fig"}A, B; *p \<* 0.001). Furthermore, we confirmed that *AhR* knock-down leads to increased COL4 *α*4 (*COL4A4*) expression in, and secretion from, ARPE19 as well as RF/6A cells ([Figure 7](#fig07){ref-type="fig"}C--F; *AhR p \<* 0.0001, *COL4A4 p \<* 0.001). *AhR* knock-down also led to an increase in *COL1A1* expression in RF/6A cells ([Figure 7](#fig07){ref-type="fig"}D; *AhR p \<* 0.0001, *COL1A1 p \<* 0.001) and a decrease in matrix metalloproteinase 2 (*MMP2*) expression in both ARPE19 ([Figure 7](#fig07){ref-type="fig"}C; *p \<* 0.0001) and RF/6A cells ([Figure 7](#fig07){ref-type="fig"}D; *p \<* 0.0001). Finally, to distinguish between COL4 associated with vascular basement membrane versus the extracellular matrix of the CNV lesion, we examined the immunolocalization pattern of the blood vessel markers smooth muscle protein 22*α* (transgelin-TAGLN) and *α*-smooth muscle actin (ACTA2) within CNV lesions of *AhR^−/−^* and wt mice (see supplementary material, [Figure S7](#sd8){ref-type="supplementary-material"}). No genotype-specific differences in the staining pattern were seen, supporting the finding that increased COL4 is a not a consequence of an increase in the number of vessels and/or associated vascular basement membranes.

![*AhR* regulates ECM deposition, production and secretion. (A) COL4 immunolocalization (red) in CNV lesions of wt and *AhR^−/−^* mice: dotted oval demarcates the lesion area; nuclei are stained blue with Hoechst; representative images are shown; scale bar = 50 µm. (B) COL4 staining intensity was quantified in the CNV lesions of wt and *AhR^−/−^* mice using ImageJ (mean and SEM; *n =* 4/group; ^\*\*^*p \<* 0.001). (C, D) Effect of *AhR* knock-down on *COL1A1*, *COL4A4* and *MMP2* mRNA expression in (C) ARPE19 cells and (D) RF/6A cells (mean and SEM; *n =* 3; ^\*\*^*p \<* 0.001, ^\*\*\*^*p \<* 0.0001; ns, not significant). (E, F) Effect of *AhR* loss on COL4 protein levels, as evaluated by western blot in (E) ARPE19 and (F) RF/6A cell lysates and secreted media (*n =* 3): representative images are shown; ONL, outer nuclear layer; siC, control siRNA; siAhR5, AhR siRNA](path0235-0101-f7){#fig07}

Discussion
==========

AhR expression and activity not only sustains important cellular functions, such as cell proliferation, differentiation and migration, but also maintains vascular homeostasis and angiogenesis [@b55]--[@b60]. In this study, using *in vitro* and *in vivo* models in which *AhR* expression and activity was altered, we investigated the potential role of this receptor in the biology of wet AMD. We show that *AhR* regulates: (a) multiple pathways involved in the pathogenesis of wet AMD; and (b) the formation and severity of neovascular lesions in an animal model of CNV. Further, *AhR* knock-down increases the ability of endothelial cells to migrate and form tube-like structures in a 3D matrix *in vitro*, an activity that results in an alteration of the RPE-choroid microenvironment. Taking into account the results from previous studies demonstrating that *AhR* activity decreases as a function of age [@b24]--[@b27], our findings support the hypothesis that targeting the AhR signalling pathway may be a viable approach to developing potential therapies to treat wet AMD patients.

The observation that *AhR* knock-out exacerbates CNV lesions in a murine model of wet AMD is novel, and verifies that the *AhR* plays an important role in maintaining both the RPE and the choroidal architecture and their responses to laser-induced injury. In some respects this is not surprising, as *AhR*-null mice develop increased ischaemia-induced angiogenesis compared to wt mice [@b61], as well as cardiac hypertrophy consequent to coronary neovascularization, concomitant with increased *VEGFA* and hypoxia-inducible factor 1*α* expression in the heart [@b62],[@b63]. However, multiple studies have shown that *AhR*-null mice have hepatic vascular defects, impaired angiogenesis, decreased cell proliferation and migration that can compromise tumour xenograft growth [@b62],[@b64]--[@b67]. This differential effect of *AhR*, resulting in pro- or anti-angiogenesis, may be cell type- and tissue-dependent [@b64]. In fact, in our cohort of *AhR^−/−^* mice, RNA expression and qPCR validation revealed a significant down-regulation of *Gpr124*, an orphan seven-pass transmembrane receptor, which has been shown to up-regulate *VEGFA* expression [@b36]. The severity of the neovascular lesions can be further explained by examining both the effect of *AhR* knock-down on RPE and choroidal endothelial cell phenotypes, as well as increased expression of pro-angiogenic factors. We found that *AhR* knock-down in ARPE19 cells did not affect cell migration (data not shown) but resulted in an increase in *VEGFA* expression. In contrast, RF/6A endothelial cells responded to *AhR* knock-down by an increase in their ability to migrate and morph into tube-like structures when plated in a 3D matrix.

Another AMD-relevant pro-angiogenic modulator is *CCL2*. This angiogenic chemokine is a critical regulator of migration of monocytes and macrophages and has also been shown to mediate *TGFβ*-induced angiogenesis [@b68]. In the eye, it has been reported to be up-regulated in aged mouse retinas [@b41],[@b42], in RPE in AMD eyes [@b69] and in the aqueous humor of CNV patients [@b70]. The larger lesions observed in our cohort of *AhR^−/−^* mice could be due in part to an increased number of Iba1^+^ microglial cells localized within the lesion subsequent to up-regulation of *CCL2* in ARPE19 cells, in concert with increased *SPP1* and *TGFB1* expression in RF/6A cells. Collectively, these observations support the postulate that AhR dysfunction exacerbates an already pro-angiogenic environment. Our findings may appear to contradict studies that have shown that AhR agonists also stimulate *CCL2* expression in human umbilical cord vein endothelial cells [@b71],[@b72]. However, this is not surprising, considering the vital role of the AhR in clearance and the fundamental phagocytic responsibility of macrophages. The inflammatory status of the macrophages recruited within the lesions, critical to their overall function [@b73],[@b74], remains to be determined.

A role for AhR in ECM remodelling has already been established; *AhR* knock-out mice develop liver fibrosis concomitant with an increase in *TGFB1* and collagen expression [@b75],[@b76]. Consistent with these reports, we also observed increased production and deposition of the ECM molecule COL4. Specifically, *AhR^−/−^* mice displayed greater COL4 deposition in the CNV lesions compared to wt mice. In addition, we measured increased COL4 synthesis and secretion in both ARPE19 and RF/6A cells following *AhR* knock-down, supporting the role of the AhR signalling pathway in mediating matrix metabolism and deposition. ECM molecules, including COL4, are of great importance in the pathobiology of AMD, as they are abundant not only within sub-RPE deposits, which increase the risk for progression to wet AMD, but also within excised CNV membranes themselves [@b77]. Although the precise link between collagen and CNV formation is not known, it has been shown in the context of vascular biology to modulate angiogenesis, promoting vascular elongation, proliferation, stabilization and survival [@b78],[@b79]. Another ECM regulatory molecule important in AMD is MMP2, whose activity is reportedly disrupted in Bruch\'s membrane isolated from human AMD donor eyes [@b80]. We observed a down-regulation of *MMP2* expression in ARPE19 and RF/6A cells with *AhR* knock-down. It should be noted that, although a decrease in COL1A1 expression was detected in our RNA-seq data, we were not able to confirm this expression change in the RPE and endothelial cell culture lines. This may not be surprising, given that we are comparing results obtained from expression studies on a complex multicellular tissue (RPE-choroid) harvested from an aged mouse to those from individual RPE or endothelial cell culture lines. Overall, our findings strengthen the hypothesis that *AhR*-mediated regulation of MMPs may contribute to impaired matrix degradation of Bruch\'s membrane and ultimately exacerbate pathology associated with AMD.

In summary, we found that decreased expression and activity of the *AhR* exacerbates murine neovascular AMD and increases cell migration and tube formation. The mechanism involves multiple AMD-related pathogenic pathways, including increased expression of pro-angiogenic mediators and altered matrix degradation. Our results suggest that the *AhR* may be important in the regulation of pathways of pathological importance in AMD. Future studies will focus on investigating the therapeutic benefits of targeting the *AhR* signalling pathway as a means of treating angiogenesis and fibrosis in wet AMD.
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AppendixS1. Supplementary materials and methods

###### 

**FigureS1.** Fetal bovine serum does not contribute to secreted protein expression. Western blots of (A) ARPE19 and (B) RF/6A cell lysates and conditioned media following *AhR* knock-down with siAhR5 were analysed for three proteins of cellular origin, AhR, GAPDH and *β*-actin. No signal was detected in the conditioned media lanes

###### 

**FigureS2.** Enlarged 3D reconstruction images of the thickness of laser-induced CNV lesions in wt and *AhR^−/−^* mice. (A) wt, single lesion; (B) *AhR^−/−^*, single lesion; and (C) *AhR^−/−^*, two merged lesions
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**FigureS3.** Validation of *AhR* knock-down using different siRNA sequences. ARPE19, primary RPE (1° RPE) and RF/6A cells were transfected with siC, siAhR1 and siAhR2. (A) *AhR* mRNA expression as determined by qPCR and (B) protein levels as determined by western blots. (C, D) mRNA expression of AhR transcriptional target genes, (C) *CYP1A2* and (D) *CYP1B1*, following *AhR* knock-down
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**FigureS4.** *AhR* knock-down does not affect cell viability and proliferation. The effect of *AhR* knock-down on cell (A) viability and (B) proliferation was determined in ARPE19, primary RPE (1° RPE) and RF/6A cells, using Cell Titer Blue® (cell viability) and ClickIt EdU® (cell proliferation) assays. Fluorescence assay activity was measured and plotted (*n =* 3). No statistical significant difference was observed between control siRNA (siC) and AhR siRNA (siAhR5)-transfected cells
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**FigureS5.** *AhR* knock-down does not lead to secretion of pro-proliferative stimuli within the media. siAhR5 was transfected into ARPE19, primary RPE (1° RPE) and RF/6A cell lines, and conditioned media (CM) were prepared 24 h later. CM was used to treat ARPE19, 1° RPE and RF/6A cells plated in 96-well plates for 3 days, followed by quantifying EdU incorporation according to the ClickIt EdU® cell proliferation assay manufacturer\'s protocol. DMEM/F12 1% FBS was used as a control for ARPE19 and 1° RPE cells. MEM 1% medium was used as a control for RF/6A cells. No significant differences were observed in cell proliferation relative to control treatments. Ctrl, control

###### 

**FigureS6.** CNV lesions in *AhR^−/−^* mouse eyes displayed an increased number of SPP1-positive cells. (A) SPP1 immunolocalization (red) in CNV lesions of 11--13 month-old wt and *AhR^−/−^* mice; nuclei were stained blue with Hoechst. Representative images are shown; scale bar = 50 µm. (B) SPP1-positive cells (arrowheads) were counted within the CNV lesions (dotted area) of wt and *AhR^−/−^* mice, using ImageJ (mean and SEM; *n =* 3/group; ^\*\*^*p \<* 0.01); IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer
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**FigureS7.** CNV lesions in wt and *AhR^−/−^* mouse eyes displayed no difference in vessel staining. Antibodies to (A, B) TAGLN (green) and (C, D) ACTA2 (green) were used as blood vessel markers and double-stained with COL4 (red) in retinal cross-sections containing a neovascular lesion, from wt and *AhR^−/−^* mouse eyes; nuclei were stained blue with Hoechst. Representative images are shown; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer
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**TableS1.** List of primers and siRNA
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**TableS2.** Antibodies, sources and applications

###### 

**TableS3.** List of mouse primers for RNA-seq validation
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**TableS4.** List of drugs, concentrations, and sources
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**TableS5.** List of differentially expressed genes and their GO classification
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